Overview
Lobbying Costs
400,000€ - 499,999€
Financial year: Jan 2021 - Dec 2021
Lobbyists (Full time equivalent)
2 Fte (4)
Lobbyists with EP accreditation
1
High-level Commission meetings
3
Lobbying Costs over the years
-
Info
Alliance for Regenerative Medicine (ARM)
EU Transparency Register
244710319190-73 First registered on 14 Oct 2015
Goals / Remit
The Alliance for Regenerative Medicine (ARM, www.alliancecerm.org) is the international advocacy organization dedicated to realizing the promise of advanced therapy medicinal products (ATMPs). ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives in Europe and globally to advance this innovative and transformative sector, which includes cell and gene therapies, and tissue-based therapies. ARM is the global voice of the sector, representing 475+ members worldwide and 85+ members across Europe, including SMEs, large companies, academic research institutions, major medical centres and patient groups.
Main EU files targeted
ARM is interested in following any legislative or policy initiative on advanced therapies, including on broader aspects which may have an impact on advanced therapies such as initiatives on pharmaceuticals, blood, tissues and cells, clinical trials, orphan medicines, health technology assessment, health data, cross-border healthcare. ARM is also interested in initiatives and policy developments relating to small and medium size enterprises and access to capital.
Address
Head Office
1015 18th Street NW Suite 1102
Washington DC 20036
UNITED STATESEU Office
2-4 Schuman Roundabout
Brussels 1040
BELGIUMWebsite
-
People
Total lobbyists declared
4
Employment time Lobbyists 100% 1 50% 1 25% 2 Lobbyists (Full time equivalent)
2
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
1 accreditations were / are live (in bold) for the selected state of 26 Sep 2023
Name Start date End Date Ms Elisabetta ZANON 13 May 2023 10 May 2024 Ms Elisabetta ZANON 24 May 2022 13 May 2023 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
Standards Coordinating Body for Gene, Cell and Regenerative Medicines and Cell-Based Drug Discovery
Foundation for Cell and Gene Medicine
National Academy of Sciences Forum on Regenerative MedicineMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2021 - Dec 2021
Lobbying costs for closed financial year
400,000€ - 499,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount finsbury glover hering 300,000€ - 399,999€ Intermediaries for current year
Name finsbury glover hering (renamed fgs global) Closed year Costs
400,000€ - 499,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Other activities
None declared
Meetings
Meetings
3 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.
-
Date 19 Sep 2023 Location Brussels, Belgium Subject Exchange of views with the Alliance for Regenerative Medicine on the implementation of the HTA Regulation as well as the reform of the EU Pharmaceutical Legislation. Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Karolina Herbout-Borczak (Cabinet member)
-
Date 27 Jan 2022 Location Brussels, virtual Subject Exchanges of views on policy priorities of the Alliance for Regenerative Medicine in Europe: the Pharmaceutical Strategy and the EU’s Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Karolina Herbout-Borczak (Cabinet member)
-
Date 08 Nov 2017 Location Brussels Subject Advanced therapy medicinal products Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)